 |
Vaccine yielded encouraging long-term survival rates in certain patients with NSCLC
April 04, 2012CHICAGO - Long-term follow-up of a phase II clinical trial showed encouraging survival in some patients with stage 3B/4 non-small cell lung cancer treated with belagenpumatucel-L, a therapeutic vaccine. The findings were presented here at the AACR Annual Meeting 2012, held March 31 - April 4.
"This is a novel immunotherapy that appears to show unusually long survival in some patients," said Lyudmila Bazhenova, M.D., associate clinical professor at the University of California-San Diego Moores Cancer Center in La Jolla, Calif.
These findings represent an updated long-term survival analysis on patients treated with belagenpumatucel-L, a cell-based allogeneic vaccine derived from four lung cancer cell lines. The open-label study included 75 patients with non-small cell lung cancer (NSCLC) - two patients with stage 2 disease, 12 with stage 3A, 15 with stage 3B and 46 with stage 4. The researchers randomly assigned patients to three dose cohorts: 1.25, 2.5 or 5 × 107 cells/injection.
For all patients, median survival was 14.5 months, and the five-year survival rate was 20 percent. The 40 patients with stage 3B/4 cancer enrolled in the second and third dose cohorts had a median survival of 15.9 months and a one-year survival rate of 61 percent, a two-year survival rate of 41 percent and a five-year survival rate of 18 percent.
Patients with stage 3B/4 nonprogressive disease after chemotherapy had a median survival of 44.4 months; five-year survival was 50 percent, which is "unheard of for patients with NSCLC," Bazhenova said.
In contrast, patients who progressed after front-line chemotherapy had a median survival rate of 14.1 months and a 9.1 percent five-year survival rate.
Bazhenova said that although these results are intriguing, they must be confirmed in a phase III clinical trial, which is currently under way in eight countries.
American Association for Cancer Research
Related Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles
New treatment holds promise for resistant lung cancer
A new chemotherapy regimen appears to produce minimal side effects in patients with lung cancer that has not responded to previous therapy, paving the way for additional research to determine if the new regimen also helps shrink tumors.
Low levels of serum bilirubin spell higher lung cancer risk for male smokers
Elevated levels of bilirubin in the blood get attention in the clinic because they often indicate that something has gone wrong with the liver.
Researchers uncover a genetic vulnerability of lung cancer
Physician-researchers at UT Southwestern Medical Center have identified a vulnerability of certain lung-cancer cells - a specific genetic weakness that can be exploited for new therapies.
Genetic vulnerability of lung cancer to lay foundation for new drug options
Physician-researchers at UT Southwestern Medical Center have identified a vulnerability of certain lung-cancer cells - a specific genetic weakness that can be exploited for new therapies.
Cisplatin-resistant cancer cells sensitive to experimental anticancer drugs, PARP inhibitors
Poly (ADP-ribose) polymerase inhibitors may be a novel treatment strategy for patients with cancer that has become resistant to the commonly used chemotherapy drug cisplatin, according to data from a preclinical study published in Cancer Research, a journal of the American Association for Cancer Research.
Pathologists identify patterns of mutations to help inform design of future trials
Molecular driven therapeutic targets have resulted in a paradigm shift in the treatment of advanced lung adenocarcinoma.
Greater representation of elderly patients in Phase III trials are needed
The median age of patients diagnosed with advanced non-small-cell lung cancer (NSCLC) has steadily increased over the recent years and is presently 70 years.
Moffitt Cancer Center Researchers Find Potential New Therapeutic Target for Treating Non-Small Cell Lung Cancer
Researchers at Moffitt Cancer Center have found a potential targeted therapy for patients with tobacco-associated non-small cell lung cancer. It is based on the newly identified oncogene IKBKE, which helps regulate immune response.
SUVmax provides valuable indicator of progression-free survival in stage I non-small cell lung cancer patients
SUVmax (Maximum Standardized Uptake Value) may be a significant and clinically independent marker to indicate progression-free survival in stage I non-small cell lung cancer (NSCLC) patients treated with stereotactic body radiation therapy (SBRT), according to research being presented at the 2013 Cancer Imaging and Radiation Therapy Symposium.
Diabetes drug could hold promise for lung cancer patients
Ever since discovering a decade ago that a gene altered in lung cancer regulated an enzyme used in therapies against diabetes, Reuben Shaw has wondered if drugs originally designed to treat metabolic diseases could also work against cancer.
More Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles
 |
Non-Small Cell Lung Cancer: Across the Continuum of Care by Asante Communications, LLC This Clinical Resource Tool is structured around consensus statements developed by the Non-Small Cell Lung Cancer (NSCLC) Working Group, a panel of oncologists with particular expertise in the multidimensional care of patients with advanced lung cancer. Using a modified Delphi process, the NSCLC Working Group has consolidated published evidence and expert clinical experience on critical issues pertaining to the comprehensive assessment of patients with advanced NSCLC, formulation of appropriate treatment regimens, implementation of maintenance therapy, and therapeutic alliances among pathologists, oncologists, and pulmonologists. The consensus statements and accompanying resources are intended as a practical companion to current guidelines, helping clinicians individualize best-practice... |
 |
Medifocus Guidebook on: Non-Small Cell Lung Cancer by Medifocus.com (Author), Elliot Jacob PhD. (Editor) The MediFocus Guidebook on Non-Small Cell Lung Cancer is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Non-Small Cell Lung Cancer, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Non-Small Cell Lung Cancer, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts,... |
 |
Medifocus Guidebook on: Small Cell Lung Cancer by Medifocus.com (Author), Elliot Jacob PhD. (Editor) The MediFocus Guidebook on Small Cell Lung Cancer is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Small Cell Lung Cancer, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Small Cell Lung Cancer, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts,... |
 |
Lung Cancer: Causes, Symptoms, Signs, Diagnosis, Treatments, Stages Of Lung Cancer - Revised Edition - Illustrated by S. Smith by Department of Health and Human Services (Author), National Institutes of Health (Author), National Cancer Institute (Author), S. Smith (Editor), S. Smith (Editor) |
 |
Systemic Treatment of Non-Small Cell Lung Cancer (Oxford Oncology Library) by Giuseppe Giaccone (Author) Lung cancer is the leading cause of cancer mortality worldwide, and non-small cell lung cancer (NSCLC) accounts for about 85% of all cases of lung cancer. Most patients present with advanced disease and five-year survival is low at about 15%. Surgery is the main treatment for early stage disease. If patients are deemed inoperable, systemic chemotherapy is considered. For patients with locally advanced disease, multimodality therapy is administered where chemotherapy is given in combination with definitive radiation therapy or surgery in selected cases. Cytotoxic chemotherapy regimens mainly consist of a platinum doublet. Biologic agents are increasingly being incorporated into treatment regimens. This pocketbook summarises the latest evidence-based and practical information on the... |
 |
What You Need to Know About Small Cell Lung Cancer - It's Your Life, Live It! (Volume 1) by Michael Braham (Author) Selecting the right treatment can literally make the difference between life and death. It is important to have the peace-of-mind knowing that you have done everything possible to help fight Small Cell Lung cancer successfully. The Cancer Group Institute's book explains, in plain English, the definition, types, frequency, risk factors, symptoms, historic and latest effective treatment for Small Cell Lung cancer. We describe surgery, radiation, chemotherapy and immune therapies. We tell you everything you must know to help make the right choices today for a Small Cell Lung cancer problem. Some of the Department Heads, Hospitals and Residents using our materials are Mayo Clinic, Harvard University, Columbia, NYU, UCLA, Johns Hopkins, MD Anderson Cancer Center Orlando, Tift Regional... |
 |
Lung Cancer: A Guide to Diagnosis and Treatment by Walter J. Scott MD (Author) What is my prognosis? What are my treatment options? Which therapies would be the most effective for my stage of lung cancer? These and other frequently asked questions are addressed in this crucial reference designed to help patients educate themselves and obtain the best possible treatments. The completely revised second edition has been updated to include a discussion of the movement towards customized chemotherapy; treatment options for early-stage lung cancer including minimally invasive surgery; and the most promising treatments, among them multimodality therapy—a combination of surgery, chemotherapy, and radiation. Dr. Scott also surveys tests for early detection of lung cancer, talks about the importance of cancer staging, examines alternative treatments, and offers advice on... |
 |
The Official Patient's Sourcebook on Non-Small Cell Lung Cancer: A Revised and Updated Directory for the Internet Age by Icon Health Publications (Author) This sourcebook has been created for patients who have decided to make education and Internet-based research an integral part of the treatment process. Although it gives information useful to doctors, caregivers and other health professionals, it also tells patients where and how to look for information covering virtually all topics related to non-small cell lung cancer, from the essentials to the most advanced areas of research. The title of this book includes the word official. This reflects the fact that the sourcebook draws from public, academic, government, and peer-reviewed research. Selected readings from various agencies are reproduced to give you some of the latest official information available to date on non-small cell lung cancer. Following an introductory chapter, the... |
|
Non-Small Cell Lung Cancer Treatment (Uni-Med Science) by Christian Manegold (Author) | |
 |
Lung Cancer: Myths, Facts, Choices--and Hope by Claudia I. Henschke (Author), Peggy McCarthy (Author), Sarah Wernick (Contributor) An authoritative book with new lifesaving strategies for those at risk and those already diagnosed.Lung cancer kills more women than breast cancer, more men than prostate cancer. This authoritative book presents new lifesaving strategies for those already diagnosed and those at risk (including ex-smokers). Lung cancer is deadly because it's usually found late. Dr. Claudia Henschke's groundbreaking research on early diagnosis, published in Lancet, made headlines worldwide. Now, for the first time, she offers specific recommendations based on her latest findings: who needs to be checked and how to get tested. People with lung cancer often are told, "Nothing can be done." Not so! Dr. Henschke and coauthor Peggy McCarthy, a leading patient advocate, provide... |
| © 2013 BrightSurf.com |